MATRIX METALLOPROTEINASE REQUIREMENTS for NEUROMUSCULAR SYNAPTOGENESIS by Mary Lynn Dear Dissertation Submitted to the Faculty O

Total Page:16

File Type:pdf, Size:1020Kb

Load more

MATRIX METALLOPROTEINASE REQUIREMENTS FOR NEUROMUSCULAR SYNAPTOGENESIS
By
Mary Lynn Dear

Dissertation
Submitted to the Faculty of the
Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of
DOCTOR OF PHILOSOPHY in
Biological Sciences January 31, 2018 Nashville, Tennessee

Approved:
Todd Graham, Ph.D. Kendal Broadie, Ph.D.
Katherine Friedman, Ph.D. Barbara Fingleton, Ph.D. Jared Nordman, Ph.D.
Copyright © 2018 by Mary Lynn Dear
All Rights Reserved
ACKNOWLEDGEMENTS
I would like to acknowledge my advisor, Kendal Broadie, and the entire Broadie laboratory, both past and present, for their endless support, engaging conversations, thoughtful suggestions and constant encouragement. I would also like to thank my committee members both past and present for playing such a pivotal role in my graduate career and growth as a scientist. I thank the Department of Biological Sciences for fostering my graduate education. I thank the entire protease community for their continued support, helpful suggestions and collaborative efforts that helped my project move forward. I would like to acknowledge Dr. Andrea Page-McCaw and her entire laboratory for helpful suggestions, being engaged in my studies and providing many tools that were invaluable to my project. I thank my parents, Leisa Justus and Raymond Dear, my brother Jake Dear and my best friend Jenna Kaufman. Words cannot describe how grateful I am for your support and encouragement. Most importantly, I would like to thank my husband, Jeffrey Thomas, for always believing in me, your unwavering support and for helping me endure all the ups and downs that come with graduate school. I am forever grateful and could not have done this without you.

iii

ACKNOWLEDGEMENT OF FUNDING
This work was supported by the National Institutes of Health R01 MH096832 and R01 MH084989 to K.B.

PUBLICATIONS
Two classes of matrix metalloproteinases reciprocally regulate synaptogenesis. Dear ML, Dani N, Parkinson W, Zhou S, Broadie K. Development. 2016 Jan 1;143(1):75-87.

Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model. Parkinson WM, Dookwah M, Dear ML, Gatto CL, Aoki K, Tiemeyer M, Broadie K. Dis Model Mech. 2016 May 1;9(5):513-27.

Neuronal activity drives FMRP- and HSPG-dependent matrix metalloproteinase function required for rapid synaptogenesis. Dear ML, Shilts J, Broadie K. Sci. Signal. 2017 Nov 7;10:eaan3181.

iv

TABLE OF CONTENTS
Page
ACKNOWLEDGEMENTS...................................................................................................................iii ACKNOWLEDGEMENT OF FUNDING...............................................................................................iv PUBLICATIONS.................................................................................................................................iv LIST OF FIGURES AND TABLES.......................................................................................................viii LIST OF SUPPLEMENTARY MATERIAL...............................................................................................x LIST OF ABBREVIATIONS .................................................................................................................xi

Chapter I. Introduction................................................................................................................................ 1
The Extracellular Matrix ............................................................................................................. 1 Characterizing the Extracellular Matrix................................................................................... 1 Core Matrisome Components.................................................................................................... 5 Collagens.................................................................................................................................. 5 Proteoglycans .......................................................................................................................... 6 Glycoproteins........................................................................................................................... 8 Matrisome Associated Molecules .............................................................................................. 9 Extracellular Matrix Receptors................................................................................................ 9 Extracellular Matrix Modifying Enzymes............................................................................... 12 The Drosophila Neuromuscular Junction as a Genetic Model Synapse................................... 18 The NMJ System .................................................................................................................... 18 Structural Synaptogenesis..................................................................................................... 21 Functional Synaptogenesis.................................................................................................... 22 Wnt Trans-Synaptic Signaling................................................................................................ 25 Heparan Sulfate Proteoglycans in Synaptic Development....................................................... 32 Secreted HSPGs ..................................................................................................................... 32 Membrane-tethered HSPGs .................................................................................................. 34 HS Biosynthesis and HS-modifying Enzymes......................................................................... 35 Matrix Metalloproteinases in Neural Development ................................................................ 35 Thesis Outline........................................................................................................................... 44

v

Part One................................................................................................................................. 44 Part Two................................................................................................................................. 44 References................................................................................................................................ 45

II. Two Classes of Matrix Metalloproteinases Reciprocally Regulate Synaptogenesis ................ 75
Summary................................................................................................................................... 76 Introduction.............................................................................................................................. 76 Materials and Methods ............................................................................................................ 78 Drosophila Stocks .................................................................................................................. 78 Antibody Production ............................................................................................................. 78 Western Blot Analyses........................................................................................................... 80 Immunocytochemistry Imaging............................................................................................. 80 Electrophysiology .................................................................................................................. 81 Electron Microscopy.............................................................................................................. 81 Statistical Measurements...................................................................................................... 81 Results ...................................................................................................................................... 82 Mmp1 and Mmp2 both regulate synapse morphogenesis................................................... 82 Mmp1 and Mmp2 both regulate differentiation of synapse function ................................. 85 Mmp1 and Mmp2 both regulate synapse molecular assembly............................................ 87 Mmp1, Mmp2 and Timp co-dependently localize to the NMJ synaptomatrix..................... 90 Mmp1 and Mmp2 restrict Wnt trans-synaptic signaling ...................................................... 93 Restoring Wnt co-receptor Dlp levels in Mmp mutants prevents synaptogenic defects..... 97 Discussion................................................................................................................................. 99 References.............................................................................................................................. 102

III. Neuronal Activity Drives FMRP- and HSPG-dependent Matrix Metalloproteinase Function
Required for Rapid Synaptogenesis ....................................................................................... 109 Summary................................................................................................................................. 110 Introduction............................................................................................................................ 110 Materials and Methods .......................................................................................................... 112 Drosophila Genetics............................................................................................................. 112 Activity Manipulations......................................................................................................... 113

vi

Immunocytochemistry Confocal Imaging ........................................................................... 113 Synaptic In Situ Zymography ............................................................................................... 114 Quantification and Statistical Analyses ............................................................................... 115 Results .................................................................................................................................... 116 Mmp1 is required for rapid activity-dependent synaptic bouton formation ..................... 116 Co-localized Mmp1 and Dlp exhibit positive activity-dependent regulation ..................... 119 Dlp localizes Mmp1 in synaptic domains and bidirectionally promotes Mmp1 intensity.. 123 Dlp is required for the rapid, activity-dependent increase of synaptic Mmp1................... 126 Synaptic Dlp bidirectionally determines proteolytic function at the NMJ.......................... 129 FMRP regulation of activity-dependent synaptic Mmp1 requires Dlp function................. 131 Discussion............................................................................................................................... 134 References.............................................................................................................................. 137

IV. Conclusions and Future Directions........................................................................................ 145
Regulation of Mmp and Timp Expression .............................................................................. 146 Mmp Regulation of Presynaptic and Postsynaptic Molecular Machinery............................. 153 Heparan Sulfate and Wingless Regulation of Mmp1 ............................................................. 158 Mmps and Activity-dependent Synaptogenesis .................................................................... 165 HSPGs and Activity-dependent Synaptogenesis .................................................................... 167 FMRP Regulation of Mmps and HSPGs .................................................................................. 168 Mmp Regulation of Other Trans-synaptic Signaling Pathways.............................................. 171 BMP trans-synaptic signaling .............................................................................................. 171 Jeb-Alk trans-synaptic signaling .......................................................................................... 175 Perspectives and Extended Future Directions ....................................................................... 178 References.............................................................................................................................. 181

Appendix A. Supplementary Material ........................................................................................................ 197

vii

LIST OF FIGURES AND TABLES

  • Figures
  • Page

1. Components of the ECM and ECM-interacting molecules ......................................................... 4 2. The Drosophila larval NMJ model synapse ............................................................................... 20 3. Cartoon schematic of a synapse at the Drosophila NMJ .......................................................... 24 4. Trans-synaptic signaling pathways driving NMJ synaptogenesis ............................................. 30 5. Cartoon schematic of the pre- and postsynaptic Wg-activated pathways at the NMJ............ 31 6. Mmps are members of the Metzincin superfamily of metalloproteinases.............................. 37 7. Drosophila Mmp structure and selected tools ......................................................................... 39 8. Overarching hypothesis ............................................................................................................ 43 9. Mmp1 and Mmp2 repress NMJ structural development......................................................... 84 10. Mmp1 and Mmp2 repress functional differentiation of the NMJ.......................................... 86 11. Mmp1 and Mmp2 modulate synaptic ultrastructural development ..................................... 89 12. Mmp1, Mmp2 and Timp exhibit co-dependent synaptic localization.................................... 92 13. Mmp1 and Mmp2 restrict Wnt trans-synaptic signal transduction ....................................... 95 14. Mmp1 and Mmp2 reciprocally regulate Wnt HSPG co-receptor Dlp..................................... 96 15. Restoring Dlp levels in Mmp mutants prevents defects in NMJ structure or function.......... 98 16. Mmp1 is required for rapid activity-dependent synaptic bouton formation....................... 118 17. Synaptic Mmp1 is rapidly increased following acute neuronal stimulation ........................ 121

18. Mꢀpꢁ aꢂd Dlp ꢃo-loꢃalizatioꢂ iꢂ syꢂaptiꢃ suꢄdoꢀaiꢂs is iꢂꢃꢅeased ꢄy aꢃute aꢃtiꢆity ........ 122 19. Syꢂaptiꢃ Dlp positiꢆely aꢂd ꢄidiꢅeꢃtioꢂally ꢅegulates seꢃꢅeted Mꢀpꢁ aꢄuꢂdaꢂꢃe.............. 125 20. Dlp is ꢅeꢇuiꢅed foꢅ the aꢃtiꢆity-depeꢂdeꢂt syꢂaptiꢃ Mꢀpꢁ ꢅegulatioꢂ................................ 128 21. Dlp positiꢆely aꢂd ꢄidiꢅeꢃtioꢂally ꢅegulates pꢅoteolytiꢃ aꢃtiꢆity at the syꢂapse .................. 130

22. FMRP regulation of the activity-dependent Mmp1 enhancement requires Dlp ................. 133 23. Mmps are expressed by both neuron and muscle ............................................................... 149 24. Mmp2 localizes to postsynaptic muscle nuclei..................................................................... 150 25. Mmp1 is abnormally sequestered at NMJs overexpressing Timp........................................ 151 26. Proximity ligation assay (PLA) detects protein-protein interactions.................................... 152 27. Glia-derived Mmp1 restricts NMJ growth ............................................................................ 155 28. Mmps differentially regulate GluRs at the NMJ ................................................................... 156

viii

29. Mmp1 and Mmp2 promote DLG at the NMJ........................................................................ 157 30. Reduced extracellular Mmp1 following Heparan Sulfate enzymatic digestion ................... 161 31. Mmp1 directly binds Heparan Sulfate .................................................................................. 162 32. Possible functions of Mmp-HSPG interactions ..................................................................... 163 33. Wg promotes Mmp1 at the NMJ .......................................................................................... 164 34. FMRP interacts with mmp1 but not mmp2 mRNA ............................................................... 170 35. Mmp1 restricts BMP trans-synaptic signaling ...................................................................... 174 36. Mmp2 promotes extracellular Jeb ligand and both Mmps restrict dpERK signaling ........... 177

  • Tables
  • Page

1. Raw data values for synaptic bouton number and ultrastructure ......................................... 215 2. Raw data values for functional neurotransmission and molecular assembly ........................ 217 3. Raw data values for selected IHC experiments ...................................................................... 219 4. Raw data values for in situ zymography assays...................................................................... 221 5. Raw data values for activity assays......................................................................................... 222

ix

LIST OF SUPPLEMENTARY MATERIAL

  • Supplemental Material
  • Page

1. Postsynaptic Timp expression suppresses NMJ morphology defects. ................................... 197 2. Mmp1 and Mmp2 regulate spontaneous SV fusion rate and response amplitude. .............. 198 3. Loss of Mmp1 and Mmp2 differentially regulate NMJ molecular assembly.......................... 199 4. Mmp2 negatively regulates GluRIIA-containing receptors..................................................... 200 5. Mmp1 and Mmp2 negatively regulate GluRIIB-containing receptors.................................... 201 6. Western blot characterization and specificity of Mmp2 and Timp antibodies. ..................... 202 7. Imaging characterization and specificity of Mmp2 and Timp antibodies .............................. 203 8. Characterization of Mmp1, Mmp2 and Timp localization at the NMJ ................................... 204 9. Temperature controls for dTRPA1 activity-induced synaptic bouton formation................... 205

10. Mꢀpꢈ is ꢂot ꢅeꢇuiꢅed foꢅ aꢃtiꢆity-depeꢂdeꢂt syꢂaptiꢃ ꢄoutoꢂ foꢅꢀatioꢂ.......................... 206

11. Mmp1 is rapidly and specifically increased following dTRPA1 neuronal stimulation.......... 207

12. Synaptic Mꢀpꢈ is ꢅapidly ꢅeduꢃed folloꢉiꢂg aꢃute ꢂeuꢅoꢂal stiꢀulatioꢂ ........................... 208 13. Syꢂaptiꢃ Dlp is ꢅapidly iꢂꢃꢅeased folloꢉiꢂg aꢃute ꢂeuꢅoꢂal stiꢀulatioꢂ .............................. 209

14. Synaptic Mmp1 and Dlp imaging controls at the NMJ terminal........................................... 210

15. Syꢂaptiꢃ Dlp ꢃhaꢂges ꢉith ꢄidiꢅeꢃtioꢂal dlp geꢂetiꢃ ꢀaꢂipulatioꢂs .................................... 211 16. Synaptic Mꢀpꢈ ꢃhaꢂges ꢉith ꢄidiꢅeꢃtioꢂal dlp geꢂetiꢃ ꢀaꢂipulatioꢂs............................... 212

17. Activity-dependent synaptic Dlp increase occurs in the absence of Mmp1 ........................ 213 18. Synaptic Dlp in FXS disease model is restored by single copy dlp co-removal..................... 214

x

LIST OF ABBREVIATIONS
(ADAM) (ADAMTS) (Alk) a disintegrin and metalloprotease a disintegrin and metalloprotease with thrombospondin type I-like motifs Anaplastic lymphoma kinase

  • Analysis of Variance
  • (ANOVA)

(AP-1) (aPKC) (APP)
Activator protein 1 atypical Protein kinase C β-amyloid precursor protein

  • Armadillo
  • (Arm)

  • (Arr)
  • Arrow

  • (ASD)
  • autism spectrum disorder

  • Active zone
  • (AZ)

  • (BBB)
  • blood brain barrier

  • (BL)
  • basal lamina

  • (BM)
  • basement membrane

(BMP) (BMPR) (BONCAT) (Brp)
Bone morphogenic protein Bone morphogenic protein receptor bio-orthogonal non-canonical amino acid tagging Bruchpilot

  • (BSA)
  • Bovine Serum Albumin

(CaCl2) (CAM) (CamKII) (Cas9) (cat) calcium chloride cell adhesion molecule Calcium/Calmodulin-dependent protein kinase CRISPR associated protein 9 catalytic
(cGMP) (CNS) cyclic guanosine monophosphate central nervous system
(Cow) (CRISPR) (CS)
Carrier of Wingless Clustered Regularly Interspaced Short Palindromic Repeats Chondroitin sulfate

xi

  • (CSP)
  • Cysteine String Protein

(CSPG) (Dad)
Chondroitin sulfate proteoglycan Daughters against decapentaplegic Division-abnormally delayed double heterozygous
(Dally) (dblhet) (dblRNAi) (dCask) (DCV)

double UAS-mmp1RNAi; UAS-mmp2dsRNAi1794-1R-2

Calcium/Calmodulin Dependent Serine Protein Kinase dense-core vesicle

  • (Dg)
  • Dystroglycan

(DGC) (dGRIP) (dLAR) (DLG)
Dystrophin-associated glycoprotein complex glutamate receptor interacting protein Leukocyte common antigen-related Discs-large

  • (Dlp)
  • Dally-like protein

(DNA) (dpERK) (Dpp) deoxyribonucleic acid diphosphorylated extracellular signal-related kinase Decapentaplegic
(DQ-gelatin) (Drl) dye-quenched fluorogenic gelatin Derailed
(DROP-1) (DS)
Proteoglycan-1 Dermatan sulfate
(DSPG) (dTRPA1) (Dvl)
Dermatan sulfate proteoglycan Transient receptor potential cation channel A1 Dishevelled

  • (Eag)
  • Ether a go-go

(ECM) (EDTA) (EJC)
Extracellular matrix ethylenediaminetetraacetic acid excitatory junctional current excitatory junctional potential Embryonic lethal abnormal vision Extracellular signal-related kinase
(EJP) (Elav) (ERK)

xii

(Evi/Wls/Srt) (EXT1) (FACIT) (FAK)
Evenness Interrupted/Wntless/Sprinter Exostosin-1 Fibril-associated collagen with interrupted triple helix Focal adhesion kinase Fibroblast growth factor fluorescent in situ hybridization Four-jointed
(FGF) (FISH) (Fj) (FMR1) (FMRP) (FNI) fragile X mental retardation 1 Fragile X Mental Retardation Protein Frizzled nuclear import

  • Faulty Attraction
  • (Frac)

(Frz2) (FUNCAT) (FXS)
Frizzled-2 receptor fluorescent non-canonical amino acid tagging Fragile X syndrome

  • (Fz)
  • Frizzled

(GAG) (Gbb) (GF) glycosaminoglycan Glass Bottom Boat growth factor

  • (GFP)
  • Green fluorescent protein

  • N-Acetylglucosamine
  • (GlcNAc)

(GlcNS) (GluR) (GOF) (GPI) sulfated N-Acetylglucosamine Glutamate receptor gain-of-function glycosylphosphatidylinositol Glycogen Synthase Kinase 3 Beta heparitinase
(GSK-ꢊβ) (Hep) (HEPES) (Hh)
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid Hedgehog

  • (hpx)
  • hemopexin

(HRP) (HS)
Horse Radish Peroxidase Heparan sulfate

Recommended publications
  • What Are the Roles of Metalloproteinases in Cartilage and Bone Damage? G Murphy, M H Lee

    What Are the Roles of Metalloproteinases in Cartilage and Bone Damage? G Murphy, M H Lee

    iv44 Ann Rheum Dis: first published as 10.1136/ard.2005.042465 on 20 October 2005. Downloaded from REPORT What are the roles of metalloproteinases in cartilage and bone damage? G Murphy, M H Lee ............................................................................................................................... Ann Rheum Dis 2005;64:iv44–iv47. doi: 10.1136/ard.2005.042465 enzyme moiety into an upper and a lower subdomain. A A role for metalloproteinases in the pathological destruction common five stranded beta-sheet and two alpha-helices are in diseases such as rheumatoid arthritis and osteoarthritis, always found in the upper subdomain with a further C- and the irreversible nature of the ensuing cartilage and bone terminal helix in the lower subdomain. The catalytic sites of damage, have been the focus of much investigation for the metalloproteinases, especially the MMPs, have been several decades. This has led to the development of broad targeted for the development of low molecular weight spectrum metalloproteinase inhibitors as potential therapeu- synthetic inhibitors with a zinc chelating moiety. Inhibitors tics. More recently it has been appreciated that several able to fully differentiate between individual enzymes have families of zinc dependent proteinases play significant and not been identified thus far, although a reasonable level of varied roles in the biology of the resident cells in these tissues, discrimination is now being achieved in some cases.7 Each orchestrating development, remodelling, and subsequent family does, however, have other unique domains with pathological processes. They also play key roles in the numerous roles, including the determination of physiological activity of inflammatory cells. The task of elucidating the substrate specificity, ECM, or cell surface localisation (fig 1).
  • ADAM17 Targets MMP-2 and MMP-9 Via EGFR-MEK-ERK Pathway Activation to Promote Prostate Cancer Cell Invasion

    ADAM17 Targets MMP-2 and MMP-9 Via EGFR-MEK-ERK Pathway Activation to Promote Prostate Cancer Cell Invasion

    1714 INTERNATIONAL JOURNAL OF ONCOLOGY 40: 1714-1724, 2012 ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion LI-JIE XIAO1,2*, PING LIN1*, FENG LIN1*, XIN LIU1, WEI QIN1, HAI-FENG ZOU1, LIANG GUO1, WEI LIU1, SHU-JUAN WANG1 and XIAO-GUANG YU1 1Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Harbin Medical University, 194 Xuefu Road, Harbin 150081, Heilongjiang; 2College of Life Science and Technology, Heilongjiang Bayi Agricultural University, 2 Xinyang Road, Daqing 163319, Heilongjiang, P.R. China Received September 8, 2011; Accepted November 18, 2011 DOI: 10.3892/ijo.2011.1320 Abstract. ADAM17, also known as tumor necrosis factor-α released and down-regulation of MMP-2, MMP-9. However, converting enzyme (TACE), is involved in proteolytic ectodo- these effects could be reversed by simultaneous addition of main shedding of cell surface molecules and cytokines. TGF-α. These data demonstrated that ADAM17 contributes to Although aberrant expression of ADAM17 has been shown androgen-independent prostate cancer cell invasion by shed- in various malignancies, the function of ADAM17 in prostate ding of EGFR ligand TGF-α, which subsequently activates the cancer has not been clarified. In the present study, we sought EGFR-MEK-ERK signaling pathway, leading finally to over- to elucidate whether ADAM17 contributes to prostate cancer expression of MMP-2 and MMP-9. This study suggests that the cell invasion, as well as the mechanism involved in the process. ADAM17 expression level may be a new predictive biomarker The expression pattern of ADAM17 was investigated in human of invasion and metastasis of prostate cancer, and ADAM17 prostate cancer cells.
  • Matrix Metalloproteinases in Angiogenesis: a Moving Target for Therapeutic Intervention

    Matrix Metalloproteinases in Angiogenesis: a Moving Target for Therapeutic Intervention

    Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention William G. Stetler-Stevenson J Clin Invest. 1999;103(9):1237-1241. https://doi.org/10.1172/JCI6870. Perspective Angiogenesis is the process in which new vessels emerge from existing endothelial lined vessels. This is distinct from the process of vasculogenesis in that the endothelial cells arise by proliferation from existing vessels rather than differentiating from stem cells. Angiogenesis is an invasive process that requires proteolysis of the extracellular matrix and, proliferation and migration of endothelial cells, as well as synthesis of new matrix components. During embryonic development, both vasculogenesis and angiogenesis contribute to formation of the circulatory system. In the adult, with the single exception of the reproductive cycle in women, angiogenesis is initiated only in response to a pathologic condition, such as inflammation or hypoxia. The angiogenic response is critical for progression of wound healing and rheumatoid arthritis. Angiogenesis is also a prerequisite for tumor growth and metastasis formation. Therefore, understanding the cellular events involved in angiogenesis and the molecular regulation of these events has enormous clinical implications. This understanding is providing novel therapeutic targets for the treatment of a variety of diseases, including cancer. Whatever the pathologic condition, an initiating stimulus results in the formation of a migrating solid column of endothelial cells called the vascular sprout. The advancing front of this endothelial cell column presumably focuses proteolytic activity to create a defect in the extracellular matrix, through which the advancing and proliferating column of endothelial […] Find the latest version: https://jci.me/6870/pdf Matrix metalloproteinases in angiogenesis: Perspective a moving target for therapeutic intervention SERIES Topics in angiogenesis David A.
  • Gent Forms of Metalloproteinases in Hydra

    Gent Forms of Metalloproteinases in Hydra

    Cell Research (2002); 12(3-4):163-176 http://www.cell-research.com REVIEW Structure, expression, and developmental function of early diver- gent forms of metalloproteinases in Hydra 1 2 3 4 MICHAEL P SARRAS JR , LI YAN , ALEXEY LEONTOVICH , JIN SONG ZHANG 1 Department of Anatomy and Cell Biology University of Kansas Medical Center Kansas City, Kansas 66160- 7400, USA 2 Centocor, Malvern, PA 19355, USA 3 Department of Experimental Pathology, Mayo Clinic, Rochester, MN 55904, USA 4 Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA ABSTRACT Metalloproteinases have a critical role in a broad spectrum of cellular processes ranging from the breakdown of extracellular matrix to the processing of signal transduction-related proteins. These hydro- lytic functions underlie a variety of mechanisms related to developmental processes as well as disease states. Structural analysis of metalloproteinases from both invertebrate and vertebrate species indicates that these enzymes are highly conserved and arose early during metazoan evolution. In this regard, studies from various laboratories have reported that a number of classes of metalloproteinases are found in hydra, a member of Cnidaria, the second oldest of existing animal phyla. These studies demonstrate that the hydra genome contains at least three classes of metalloproteinases to include members of the 1) astacin class, 2) matrix metalloproteinase class, and 3) neprilysin class. Functional studies indicate that these metalloproteinases play diverse and important roles in hydra morphogenesis and cell differentiation as well as specialized functions in adult polyps. This article will review the structure, expression, and function of these metalloproteinases in hydra. Key words: Hydra, metalloproteinases, development, astacin, matrix metalloproteinases, endothelin.
  • Functional and Structural Insights Into Astacin Metallopeptidases

    Functional and Structural Insights Into Astacin Metallopeptidases

    Biol. Chem., Vol. 393, pp. 1027–1041, October 2012 • Copyright © by Walter de Gruyter • Berlin • Boston. DOI 10.1515/hsz-2012-0149 Review Functional and structural insights into astacin metallopeptidases F. Xavier Gomis-R ü th 1, *, Sergio Trillo-Muyo 1 Keywords: bone morphogenetic protein; catalytic domain; and Walter St ö cker 2, * meprin; metzincin; tolloid; zinc metallopeptidase. 1 Proteolysis Lab , Molecular Biology Institute of Barcelona, CSIC, Barcelona Science Park, Helix Building, c/Baldiri Reixac, 15-21, E-08028 Barcelona , Spain Introduction: a short historical background 2 Institute of Zoology , Cell and Matrix Biology, Johannes Gutenberg University, Johannes-von-M ü ller-Weg 6, The fi rst report on the digestive protease astacin from the D-55128 Mainz , Germany European freshwater crayfi sh, Astacus astacus L. – then termed ‘ crayfi sh small-molecule protease ’ or ‘ Astacus pro- * Corresponding authors tease ’ – dates back to the late 1960s (Sonneborn et al. , 1969 ). e-mail: [email protected]; [email protected] Protein sequencing by Zwilling and co-workers in the 1980s did not reveal homology to any other protein (Titani et al. , Abstract 1987 ). Shortly after, the enzyme was identifi ed as a zinc met- allopeptidase (St ö cker et al., 1988 ), and other family mem- The astacins are a family of multi-domain metallopepti- bers emerged. The fi rst of these was bone morphogenetic β dases with manifold functions in metabolism. They are protein 1 (BMP1), a protease co-purifi ed with TGF -like either secreted or membrane-anchored and are regulated growth factors termed bone morphogenetic proteins due by being synthesized as inactive zymogens and also by co- to their capacity to induce ectopic bone formation in mice localizing protein inhibitors.
  • MMP-9) on the Metastatic Behavior of Oropharyngeal Cancer

    MMP-9) on the Metastatic Behavior of Oropharyngeal Cancer

    ANTICANCER RESEARCH 25: 4129-4134 (2005) Influence of Matrix Metalloproteinase 9 (MMP-9) on the Metastatic Behavior of Oropharyngeal Cancer A.A. DÜNNE1, A. GRÖBE1, A.M. SESTERHENN1, P. BARTH2, C. DALCHOW1 and J.A. WERNER1 1Department of Otolaryngology, Head and Neck Surgery and 2Department of Pathology, Philipps University of Marburg, Marburg, Germany Abstract. Background: The role of the single matrix molecular biological factors have been proposed for their metalloproteinases (MMPs) in the metastatic process of possible impact on the lymphogenic metastatic process. squamous cell carcinomas (SCC) is still obscure. Materials In this context, special interest is being paid to a better and Methods: The MMP-9 expression was described knowledge of the matrix metalloproteinases (MMPs) (5), immunohistochemically in 105 patients (40-79 years of age, that are involved in the physiology of reconstruction and mean: 57.84 years; 84 male, 21 female) suffering from renewal processes of surrounding tissue. In particular, MMP- oropharyngeal cancer (22x T1, 31x T2, 24x T3, 28x T4) with 2 and -9, originating from the subfamily of gelatinases, seem different neck stages (41x N0, 6x N1, 54x N2, 4x N3 neck). to play important roles in the metastatic process of several Results: A significant correlation between MMP-9 expression carcinomas (6, 7), including not only SCC of the head and and T stage (p<0.05), N stage (r=0.55, p<0.01) and UICC neck (8), but also malignant tumors of the lung (9), the stage (r=0.55, p<0.01) was revealed. Most remarkable was the prostate (10), the colon (11) and the bladder (12).
  • Identification of the Membrane-Type Matrix Metalloproteinase MT1-MMP

    Identification of the Membrane-Type Matrix Metalloproteinase MT1-MMP

    Journal of Cell Science 110, 589-596 (1997) 589 Printed in Great Britain © The Company of Biologists Limited 1997 JCS9564 Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts Takuya Sato1, Maria del Carmen Ovejero1, Peng Hou1, Anne-Marie Heegaard1, Masayoshi Kumegawa2, Niels Tækker Foged1 and Jean-Marie Delaissé1,* 1Department of Basic Research, Center for Clinical & Basic Research, Ballerup Byvej 222, DK-2750 Ballerup, Denmark 2The First Department of Oral Anatomy, Meikai University School of Dentistry, Keyakidai 1-1, Sakado, Saitama 350-02, Japan *Author for correspondence SUMMARY The osteoclasts are the cells responsible for bone resorp- on bone sections showed that MT1-MMP is expressed also tion. Matrix metalloproteinases (MMPs) appear crucial in osteoclasts in vivo. Antibodies recognizing MT1-MMP for this process. To identify possible MMP expression in reacted with specific plasma membrane areas corre- osteoclasts, we amplified osteoclast cDNA fragments sponding to lamellipodia and podosomes involved, respec- having homology with MMP genes, and used them as a tively, in migratory and attachment activities of the osteo- probe to screen a rabbit osteoclast cDNA library. We clasts. These observations highlight how cells might bring obtained a cDNA of 1,972 bp encoding a polypeptide of MT1-MMP into contact with focal points of the extracel- 582 amino acids that showed more than 92% identity to lular matrix, and are compatible with a role of MT1- human, mouse, and rat membrane-type 1 MMP (MT1- MMP in migratory and attachment activities of the osteo- MMP), a cell surface proteinase believed to trigger cancer clast. cell invasion. By northern blotting, MT1-MMP was found to be highly expressed in purified osteoclasts when compared with alveolar macrophages and bone stromal Key words: Osteoclast, MMP-14, MT1-MMP, Membrane proteinase, cells, as well as with various tissues.
  • Matrix Metalloproteinase -9, Human Recombinant, Expressed in Transfected Cells

    Matrix Metalloproteinase -9, Human Recombinant, Expressed in Transfected Cells

    Matrix Metalloproteinase -9, human recombinant, expressed in transfected cells Catalog Number M4809 Storage Temperature –70 °C EC 3.4.24.35 All MMPs are synthesized as proenzymes, and most of Synonyms: MMP-9; Gelatinase-B; 95 kDa Gelatinase them are secreted from the cells as proenzymes. Thus, the activation of these proenzymes is a critical step that Product Description leads to extracellular matrix breakdown. Human Matrix Metalloproteinase-9 (MMP-9) is a matrix metalloproteinase that has been substrate-affinity MMPs are considered to play an important role in purified from transfected cells (pro and active forms). wound healing, apoptosis, bone elongation, embryo development, uterine involution, angiogenesis,5 and Matrix Metalloproteinase-9 (MMP-9) may be used in tissue remodeling, and in diseases such as multiple various immunochemical techniques such as sclerosis,3,6 Alzheimer’s,3 malignant gliomas,3 lupus, immunoblotting, ELISA, enzyme kinetics assays, and arthritis, periodontis, glomerulonephritis, athero- substrate assays. This preparation consists primarilay sclerosis, tissue ulceration, and in cancer cell invasion of the proenzyme form, with a small amount of active and metastasis.7 Numerous studies have shown that enzyme and TIMP present. The following bands may be there is a close association between expression of detected: various members of the MMP family by tumors and MMP-9 Proenzyme (>85%) at ~88 kDa non-reduced their proliferative and invasive behavior and metastatic and 92 kDa reduced potential. minor band (MMP-9 dimer) at ~180 kDa intermediate active form (very small amounts) at The tissue inhibitors of metalloproteinases (TIMPs) are ~84 kDa non-reduced naturally occurring proteins that specifically inhibit mature active form (very small amounts) at 82 kDa matrix metalloproteinases and regulate extracellular non-reduced matrix turnover and tissue remodeling by forming tight - TIMP-1 (~10%) at 28 kDa binding inhibitory complexes with the MMPs.
  • Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis

    Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis

    Vol. 10, 7621–7628, November 15, 2004 Clinical Cancer Research 7621 Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Johanna M. Pellikainen,1,2,3 Kirsi M. Ropponen,2 positive disease. In the univariate survival analysis, positive Vesa V. Kataja,3 Jari K. Kellokoski,4 stromal MMP-9 predicted shorter recurrence-free survival and breast cancer-related survival (0.0389 ؍ RFS; P) 1,2,3,6 5 ؉ ؍ Matti J. Eskelinen, and Veli-Matti Kosma 1 (BCRS; P 0.0081) in ER disease, especially in the sub- ؍ > Department of Pathology and Forensic Medicine, University of ؉ 2 3 group of ER tumors of 2 cm in diameter (T1; P 0.0031 ؍ ,Kuopio, Kuopio, Finland; Departments of Pathology, Oncology 4Otorhinolaryngology, Oral and Maxillofacial Unit, and 5Surgery, for RFS, and P 0.0089 for BCRS). High MMP-9 expres- in the (0.0351 ؍ Kuopio University Hospital, Kuopio, Finland; and 6Department of sion in cancer cells predicted longer RFS (P Pathology, Centre for Laboratory Medicine, University of Tampere whole patient group. In the multivariate analysis of the and Tampere University Hospital, Tampere, Finland whole patient group, the independent predictors of shorter RFS were reduced MMP-9 expression in carcinoma cells ؍ ؍ ABSTRACT (P 0.0248), HER2 overexpression (P 0.0001), and ad- -Shorter BCRS was pre .(0.0002 ؍ vanced-stage disease (P Purpose: In the present study, we investigated the ex- dicted by advanced-stage disease (P < 0.0001). pression and prognostic value of matrix metalloproteinase Conclusions: Expression of MMP-2 and MMP-9 in (MMP)-2 and MMP-9 in breast cancer as well as their breast cancer seems to be partly related to expression of relation to transcription factor activator protein (AP)-2 AP-2 and HER2.
  • Methods for Detection of Matrix Metalloproteinases As Biomarkers in Cardiovascular Disease Viorica Lopez-Avila

    Methods for Detection of Matrix Metalloproteinases As Biomarkers in Cardiovascular Disease Viorica Lopez-Avila

    The University of San Francisco USF Scholarship: a digital repository @ Gleeson Library | Geschke Center Biology Faculty Publications Biology 2008 Methods for Detection of Matrix Metalloproteinases as Biomarkers in Cardiovascular Disease Viorica Lopez-Avila Juliet Spencer University of San Francisco, [email protected] Follow this and additional works at: http://repository.usfca.edu/biol_fac Part of the Biology Commons, and the Cardiovascular Diseases Commons Recommended Citation Lopez-Avila, V and Spencer, JV. Methods for Detection of Matrix Metalloproteinases as Biomarkers in Cardiovascular Disease. Clinical Medicine Insights: Cardiology 2008:2 75-87. This Article is brought to you for free and open access by the Biology at USF Scholarship: a digital repository @ Gleeson Library | Geschke Center. It has been accepted for inclusion in Biology Faculty Publications by an authorized administrator of USF Scholarship: a digital repository @ Gleeson Library | Geschke Center. For more information, please contact [email protected]. REVIEW Methods for Detection of Matrix Metalloproteinases as Biomarkers in Cardiovascular Disease Viorica Lopez-Avila1 and Juliet V. Spencer2 1Agilent Technologies, Santa Clara, CA 95051, U.S.A. 2University of San Francisco, San Francisco, CA 94403, U.S.A. Abstract: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteolytic enzymes that degrade extracel- lular matrix (ECM) components like collagen, fi bronectin, and laminin. While this activity is important for normal develop- ment, morphogenesis, and wound healing, deregulation of MMP activity has been implicated in a number of cardiovascular diseases, including congenital heart defects, atherosclerosis, myocardial infarction, and congestive heart failure. MMPs are good potential diagnostic indicators of cardiovascular disease, but current detection methods are time consuming and quite laborious.
  • Matrix Metalloproteinase-3, Catalytic Domain (M9320)

    Matrix Metalloproteinase-3, Catalytic Domain (M9320)

    Matrix Metalloproteinase-3, Catalytic Domain human, recombinant expressed in E. coli Catalog Number M9320 Storage Temperature -70 °C EC 3.4.24.17 Matrix Metalloproteinase-3 (MMP-3) degrades a wide range of substrates, including gelatin, type IV, V, IX, Synonyms: MMP-3; Stromelysin-1; Transin; and X collagens, elastin, laminin, vitronectin, casein, Proteoglycanase fibronectin, proteoglycans, aggrecan, myelin basic protein, and a-1-antitrypsin.8,9 MMP-3 can be induced Product Description by cytokines IL-1b and TNF-a, by growth factors EGF, The matrix metalloproteinases (MMPs) are a family of PDGF, and IGFBP-3, and by the tumor promotor PMA. at least eighteen secreted and membrane-bound zinc- Its expression is inhibited by TGF-b and by all-trans endopeptidases. Collectively, these enzymes can retinoic acid (RA). The MMP-3 substrate repertoire degrade all the components of the extracellular matrix, extends beyond the extracellular matrix proteins and including fibrillar and non-fibrillar collagens, fibro- suggests that MMP-3 has additional roles other than in nectin, laminin and basement membrane glyco- direct tissue remodeling (i.e., enzyme cascades and proteins. In general, a signal peptide, a propeptide, cytokine regulation). and a catalytic domain containing the highly conserved zinc-binding site characterize the structure of the MMP-3 does not cleave the triple helical region of the MMPs. In addition, fibronectin-like repeats, a hinge interstitial collagens, which is a characteristic that region, and a C-terminal hemopexin-like domain allow distinguishes the stromelysins from the collagenases. categorization of MMPs into the collagenase, gela- Structurally, MMP-3 is divided into several distinct tinase, stomelysin and membrane-type MMP sub- domains: a pro-domain which is cleaved upon 1-4 families.
  • Gelatinase B/Matrix Metalloproteinase-9 Is a Phase-Specific Effector Molecule, Independent from Fas, in Experimental Autoimmune Encephalomyelitis

    Gelatinase B/Matrix Metalloproteinase-9 Is a Phase-Specific Effector Molecule, Independent from Fas, in Experimental Autoimmune Encephalomyelitis

    bioRxiv preprint doi: https://doi.org/10.1101/321661; this version posted May 14, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitis Estefania Ugarte-Berzal1, Nele Berghmans2, Lise Boon1, Erik Martens1, Jennifer Vandooren1, Bénédicte Cauwe1, Greet Thijs1, Paul Proost2, Jo Van Damme2, Ghislain Opdenakker1 1,2 Rega Institute for Medical Research, 1Laboratory of Immunobiology, 2 Laboratory of Molecular Immunology, Department of Microbiology and Immunology, University of Leuven, KU Leuven, Belgium. Abstract Gelatinase B/matrix metalloproteinase-9 (MMP-9) triggers multiple sclerosis (MS) and the animal model of experimental autoimmune encephalomyelitis (EAE) by the breakdown of the blood-brain barrier. Interestingly, MMP-9 is beneficial in systemic autoimmunity caused by Fas-deficiency. Fas-deficient (faslpr) and Fas-ligand-deficient mice are protected against EAE. We here investigated the interaction between Fas and MMP-9 in the setting of induction of EAE and compared short- and long-term effects. We provoked EAE with myelin oligodendrocyte glycoprotein (MOG) peptide and compared EAE development in four genotypes (wild-type (WT), single knockout mmp-9-/-, faslpr, and mmp-9-/-/faslpr) and monitored leukocytes, cytokines and chemokines as immunological parameters. As expected, faslpr mice were resistant against EAE induction, whereas MMP-9 single knockout mice were not. In the double mmp-9-/-/ faslpr mice the effects on disease scores pointed to independent rather than interrelated disease mechanisms.